Abiopharma

🔍 ABERNETHY MATT (Executive)

Company: NEUROCRINE BIOSCIENCES INC (NBIX)

Report Date: 2026-01-31

Detailed Transactions and Holdings:

• Acquired 2,437 shares of Common Stock (Direct)
  Date: 2026-01-31 | Code: M | equity_swap_involved: 0 | shares_owned_after: 38,465.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 1,368 shares of Common Stock at $136.06 per share (Direct)
  Date: 2026-01-31 | Code: F | equity_swap_involved: 0 | shares_owned_after: 37,097.00 | transaction_form_type: 4 | Footnotes: F2
• Sold 2,437 shares of Restricted Stock Unit (Derivative)
  Date: 2026-01-31 | Code: M | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F3, F4, F4

Footnotes:

• F1: Includes an aggregate of 218 shares purchased on August 29, 2025 from the Neurocrine Biosciences, Inc. 2018 Employee Stock Purchase Plan.
• F2: Shares withheld by Neurocrine Biosciences, Inc. (the "Company" or "Issuer") to satisfy tax withholding requirements on vesting of restricted stock units ("RSUs"). No shares were sold.
• F3: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.
• F4: This RSU was granted to the Reporting Person on January 31, 2022. In accordance with the terms of the RSU, the award vested as to 2,436 shares on January 31, 2023, vested as to 2,436 shares on January 31, 2024, vested as to 2,436 shares on January 31, 2025, and vested as to 2,437 shares on January 31, 2026, subject to the terms and conditions of the award.